Inhaled Nitric Oxide Market Report and Forecast 2023-2031

The global inhaled nitric oxide market value was USD 740.1 million in 2022, driven by the increasing incidence of respiratory disorders across the globe. The market size is anticipated to grow at a CAGR of 8.1% during the forecast period of 2023-2031 to achieve a value of USD 1491.7 billion by 2031.

Introduction

Inhaled Nitric Oxide (iNO) is a medical gas used for the treatment of various cardiovascular and pulmonary conditions. It is a selective pulmonary vasodilator that helps improve oxygenation and blood flow in the lungs. iNO is commonly administered through inhalation therapy, where the gas is delivered directly to the patient's respiratory system.

Key Trends in the Inhaled Nitric Oxide Market

Some key trends involved in the inhaled nitric oxide market are as follows:

• Increasing Application in Neonatal Care: Inhaled Nitric Oxide has gained significant traction in the field of neonatal care, particularly in the treatment of persistent pulmonary hypertension of the newborn (PPHN). PPHN is a life-threatening condition characterized by high blood pressure in the blood vessels of the lungs. iNO has shown to effectively relax the pulmonary arteries, improving oxygenation and reducing the need for invasive procedures in newborns
• Emerging Use in Adult Respiratory Distress Syndrome (ARDS): In recent years, there has been growing interest in using inhaled nitric oxide for the treatment of acute respiratory distress syndrome (ARDS) in adults. ARDS is a severe lung condition that can occur due to various causes, including pneumonia, sepsis, or trauma. iNO has shown potential in improving oxygenation and lung function in ARDS patients, although further research is still ongoing to establish its efficacy and safety
• Technological Advancements: The market for inhaled nitric oxide is witnessing technological advancements in delivery systems and monitoring devices. Manufacturers are developing innovative delivery systems that offer precise and controlled dosing of iNO, ensuring optimal therapeutic outcomes. Additionally, advancements in monitoring devices and sensors enable real-time monitoring of the patient's response to iNO therapy, allowing healthcare providers to adjust the dosage as needed
• Growing Adoption in Cardiac Surgery: Inhaled Nitric Oxide has found application in cardiac surgery, specifically in cases where pulmonary hypertension is a concern. It is used during cardiopulmonary bypass procedures to improve oxygenation and reduce the risk of pulmonary complications. The use of iNO in cardiac surgery has shown promise in improving patient outcomes and reducing post-operative complications

Inhaled Nitric Oxide Market Segmentations

Market Breakup by Purity

• 99.92% Purity
• 99.99% Purity
• Others

Market Breakup by Applications

• Chronic Obstructive Pulmonary Disease (COPD)
• Neonatal Respiratory Treatment
• Tuberculosis Treatment
• Acute Respiratory Distress Syndrome (ARDS)
• Malaria Treatment
• Others

Market Breakup by End User

• Clinics
• Hospitals
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Inhaled Nitric Oxide Market Scenario

The inhaled nitric oxide (iNO) market is a rapidly growing segment of the healthcare industry, driven by the increasing prevalence of cardiovascular and pulmonary diseases and the growing adoption of iNO therapy as an effective treatment option. Inhaled nitric oxide is a selective pulmonary vasodilator that helps improve oxygenation and blood flow in the lungs, making it a valuable tool in the management of various conditions.

The market for inhaled nitric oxide is driven by several factors. Firstly, there is a growing awareness among healthcare professionals about the benefits of iNO therapy, leading to increased adoption and utilization. Additionally, advancements in technology and delivery systems have made iNO therapy more accessible and convenient for both patients and healthcare providers.

One key driver of the market is the rising incidence of respiratory disorders, such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. These conditions require effective therapies to improve lung function and oxygenation, and iNO has demonstrated promising results in managing these disorders.

Inhaled Nitric Oxide Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Mallinckrodt
• Linde plc
• Air Liquide
• BOC Limited
• Bellerophon Therapeutics
• Beyond Air Inc
• Halma plc
• VERO Biotech,
• Nu-Med Plus
• Getinge AB
• Merck KGaA
• Genosys Informatics
• Geno
• Perma Pure LLC